Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.48 |
| ▸ | IDO1 | P14902 | 3/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PYGL | P06737 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5544401 | 0.88 | IGF1R (0.53) | PNMTTAAR1SIGMAR1IDO1IGF1R | |
| SCHEMBL5545863 | 0.86 | IGF1R (0.56) | PNMTTAAR1SIGMAR1IDO1IGF1R | |
| SCHEMBL5539473 | 0.85 | IGF1R (0.54) | PNMTTAAR1SIGMAR1IDO1IGF1R | |
| SCHEMBL2701205 | 0.82 | PNMT (0.37) | PNMTTAAR1SIGMAR1CYP1A2MEN1 | |
| SCHEMBL95777 | 0.82 | PNMT (0.46) | PNMTTAAR1SIGMAR1IDO1IGF1R | |
| SCHEMBL95778 | 0.82 | PNMT (0.46) | PNMTTAAR1SIGMAR1IDO1IGF1R | |
| SCHEMBL97464 | 0.78 | PNMT (0.54) | PNMTTAAR1SIGMAR1IDO1IGF1R | |
| SCHEMBL9206133 | 0.77 | GFER (0.36) | TAAR1CYP1A2MEN1KMT2A | |
| SCHEMBL7328450 | 0.76 | PNMT (0.61) | PNMTTAAR1SIGMAR1IDO1IGF1R | |
| SCHEMBL440374 | 0.76 | TAAR1 (0.50) | TAAR1IDO1IGF1RALOX15CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5672582-A | ANTICOAGULANTS; 4-SUBSTITUTED CYCLOHEXYLAMINE DERIVATIVES | MERCK & CO., INC. (US) | 1997-09-30 | — | — | US | claimed |
| WO-1996011697-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1996-04-25 | — | — | WO | claimed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-5672582-A | ANTICOAGULANTS; 4-SUBSTITUTED CYCLOHEXYLAMINE DERIVATIVES | MERCK & CO., INC. (US) | 1997-09-30 | — | — | US | disclosed |
| WO-1996011697-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1996-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | PNMT 4701/4885TAAR1 364/4885SIGMAR1 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.